Table 3.

Parameter estimates and bootstrap analysis of the blinatumomab population pharmacokinetic parameters (n = 674)

Parameter	Final model (mean (RSE, %) [95% CI])	Non-parametric bootstrap: 500 successful of 500 replicates (median [95% CI])
Pharmacokinetic parameters
Volume (L)	5.98 (8.86) [5.14–6.98]	5.99 [5.14–6.98]
CL (L/h)	2.22 (2.95) [2.08–2.35]	2.22 [2.08–2.35]
Effect of BSA on CL (θ)a	0.620 (12.7) [0.46–0.76]	0.625 [0.463–0.756]
Inter-individual variability (%CV)
ωCL	47.6 (16.1) [38.1–54.2]	47.1 [38.1–54.1]
ωEPS	64.3 (14.5) [55.0–73.0]	64.4 [55.0–73.0]
Residual variability (%CV)	55.9 (3.99) [52.6–61.5]	56.1 [46.3–75.6]

BSA body surface area, CI confidence interval obtained from NONMEM^® asymptotic standard errors, CL clearance, CV coefficient of variation, RSE relative standard error, ωCL inter-subject variability in CL, ωEPS inter-subject variability in residual variability

^aCL_individual = CL·(BSA/1.876)^{Effect of BSA on CL}